Top Tweets for #Pdl1
Roche Tecentriq Colon Cancer Milestone:
Full data analysis on BiotechReality:
https://t.co/WIgf2VZfuC
#Roche #Tecentriq #TecentriqHybreza #Atezolizumab #FDAApproval #dMMR #MSIH #ColorectalCancer #AdjuvantTherapy #PDL1 #ATOMICTrial #Phase3 #Oncology #BiotechReality
How is #PDL1 controlled beyond transcription?
This review explores its #PostTranslationalModifications and crosstalk, revealing mechanisms of immune escape and potential immunotherapy targets. @x.z.m.u @sjtu1896
#GenesAndDiseases: https://t.co/yGB4h7Qkx3
Why do some #LungCancers resist PD-1/PD-L1 #immunotherapy?
This study identifies ANP32A as a regulator of #PDL1, showing that its loss enhances EP300/CREBBP activity & may influence treatment response. @FudanUniversity
#GenesAndDiseases: https://t.co/csteXmyw94
⚠️ FDA just approved today #Belzutifan and #Lenvatinivlb for clear cell #renal cancer following PD to #PDL1 or #PD1 inhibitor @FDADrugs @FDA
📈 Based on data from #LITESPARK11
🧍🏽♂️🧍🏽♀️n = 747
✔️ PFS 14.6 vs 10.6m (HR 0.74)
@ASCO @myESMO @_SEOM @OncoAlert
More info 👇🏽
https://t.co/upclQt6N6K
#IHC #PulmPath #PDL1 #Pathresidents
Excellent educational video ,again by our guru @smlungpathguy ↘️
🚨🔥@OncoAlert Hot off the press.
#BigNews #PressRelease by @SMMT_TX
⭐️ #HARMONi2 phase 3 trial of 1st line #Ivonescimab vs #Pembrolizumab in pts with #PDL1+ advanced non-small-cell #LungCancer (which previously showed #PFS benefit) now showing:
✅Statistically Significant ⬆️
#OverallSurvival (#OS) Benefit
👇🏻
https://t.co/CQejBTqLn3
🚨🔥@OncoAlert Hot off the press
Just published @TheLancet
Results of #HARMONi2 phase 3 trial of #Ivonescimab (#PD1 & #VEGF Ab) vs #Pembrolizumab in pts with #PDL1+ advanced non-small cell #LungCancer in China.
⬆️#mPFS: 11.1 vs 5.8 months #HR: 0.51
👇🏻
https://t.co/I2qVjQ0u6M
Tankul & Hanamornroongruang et al. evaluated correlation between expression of PD-L1 and clinicopathological, surgical outcomes & oncologic outcomes in patients with epithelial ovarian carcinoma.
https://t.co/DXP01WCTH1
#CancerReports #Wiley #OvarianCarcinoma #PDL1
🌟As presented at #AAIC2026: A phase 1b trial shows that IBC-Ab002, a short lived anti-#PDL1 antibody that intermittently activates the peripheral #ImmuneSystem is safe and well tolerated in people with early #Alzheimers disease. #AlzheimersDisease, #Neuroimmunology #ImmuneCheckpoint #ClinicalTrials
https://t.co/mJ0uOXyPP5
ISMRM: Predictive model evaluates PD-L1 status in breast cancer: https://t.co/6Qxglir96v
More from the 2026 ISMRM & ISMRT Annual Meeting & Exhibition at Aunt Minnie: https://t.co/pJhfAM9SIw
#ISMRM2026 #ISMRT2026 #BreastCancer #MedicalImaging #Radiology #MRI #PDL1 #CancerResearch
🔥🚨@OncoAlert Hot off the press.
Just published @TheLancet in conjunction with presentation @ASCO #ASCO26
⭐️Interim Analysis of phase 3 trial;
#OptiTROP-#Lung05 of:
❇️#Sacituzumab Tirumotecan (Sac-TMT)+ #Pembrolizumab Vs #Pembrolizumab in #PDL1+ advanced non-small-cell #LungCancer.
✅#mPFS (Not reached) vs 5.7m (HR 0.35)
✅#ORR 70.2% vs 42.0%
✅Immature #OS data; Positive trend
(HR 0.55)
🔴 ≥ Grade 3 Tx emergent #AEs:
55% vs 31%
👇🏻
https://t.co/OZWx44hNtU
Pulmopath: molecular testing basic notes #pulmopath #EGFR #ALK #ROS1 #RET #MET #Her2 #BRAF #PDL1 #Lung #WCLC #pathology #pathognosis
#Ovariancancer finally got its first OS benefit from #immunotherapy.
#KEYNOTE_B96: #pembrolizumab plus weekly paclitaxel+/- Bev. HR 0.76 in CPS ≥1. HR 0.82 ITT. Lancet, tonight at #SGO2026.
** Two prior phase 3 ICI trials in this disease failed. Both targeted #PDL1. #Pembrolizumab targets #PD1. The backbone also differed->weekly paclitaxel primes the tumor immune microenvironment in ways PLD does not.
😵💫Two variables. One result. We cannot fully separate
them yet.
And now the question no trial has answered: #pembrolizumab is approved. #Mirvetuximab is approved. #Relacorilant just showed OS benefit. Three active regimens with survival data in platinum-resistant ovarian cancer.
Zero sequencing data. Zero biomarker algorithm to tell you which patient gets which drug first.
#SGO2026 #GynOnc #Oncology #MedTwitter @SGO_org @gynoncjnls @gyncsm @TheLancetOncol
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.9M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.6M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers